Clinical trials · New York, NY
Advanced or Metastatic Solid Tumors clinical trials in New York
We’re tracking 619 recruiting advanced or metastatic solid tumors studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
New York, New YorkAges 18 years+ - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
New York, New YorkAges 15 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
New York, New YorkAges 18 years+ - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT06716138RecruitingPhase 1
ANS03 for solid tumors with ROS1 or NTRK changes
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
New York, New YorkAges 18–90 - NCT07195682RecruitingPhase 1
Study of an experimental drug for advanced kidney cancer
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
New York, New YorkAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
New York, New YorkAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
New York, New YorkAges 16 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
New York, New YorkAges 18 years+ - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
New York, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
New York, New YorkAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
New York, New YorkAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
New York, New YorkAges 18 years+ - NCT07204340RecruitingPhase 1
TLN-372 for advanced KRAS-mutant solid tumors
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
New York, New YorkAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
New York, New YorkAges 18 years+ - NCT01639508RecruitingPhase 2
Cabozantinib for lung cancer with specific gene changes
This trial studies how well cabozantinib works in advanced lung cancer when the tumor has certain gene changes (like RET, ROS1, NTRK, MET, or AXL). It may help slow tumor growth after standard treatments, depending on your tumor test results.
New York, New YorkAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
New York, New YorkAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
New York, New YorkAges 1–21 - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
New York, New YorkAges 6 months–25 years - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
New York, New YorkAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Memorial Sloan Kettering Cancer Center · 13 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Memorial Sloan Kettering Basking Ridge · 2 studies
- Memorial Sloan Kettering Bergen · 2 studies
- Memorial Sloan Kettering Commack · 2 studies
- Memorial Sloan Kettering Monmouth · 2 studies
- Memorial Sloan Kettering Nassau · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in New York.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near New York?
- Yes. We're currently tracking 619 recruiting advanced or metastatic solid tumors studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.